Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199) / MK-3475-199 Pembro Prostata
Jul 27, 2016This is a nonrandomized, multinational, open-label trial of pembrolizumab (MK-3475) in subjects with metastatic cas-tration-resistant prostate cancer (mCRPC) previously treated with docetaxel-based chemotherapy. The trial will be conducted in conform...
Clinical Studies - Jul 27, 2016 - Jun 30, 2019
Automatically Closed
Project leader: Omlin Aurelius
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558, anti PD-1 Monoclonal Anti-body) in Advanced Solid Tumors
Jul 21, 2016This is a Phase 1/2a, open-label study of BMS-986156 administered as a single agent and in combination with nivolumab in subjects with advanced solid tumors. The study will be conducted in 4 parts. Parts A and B will consist of dose escalation with B...
Clinical Studies - Jul 21, 2016 - Sep 30, 2017
Automatically Closed
Project leader: Jörger Markus
Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer (IMIT)
Jul 15, 2016
Clinical Studies - Jul 15, 2016 - Oct 15, 2019
Automatically Closed
Project leader: Flatz Lukas
Members: Diem Stefan
An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA (Abi-RE)
Jun 12, 2016Clinical Trial with an IMP, risk category B according to HRA. Abiraterone acetate (AA) is a standard treatment option both in chemotherapy naïve and docetaxel pre-treated men with metastatic castrate-resistant prostate cancer (CRPC). With the approva...
Clinical Studies - Jun 12, 2016 - Dec 31, 2017
Automatically Closed
Project leader: Omlin Aurelius
SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
Jun 3, 2016GRAALL-2014 follows the GRAALL-2003 and 2005 trials. The GRAALL-2014 trial is subdivided in three sub-studies: GRAALL-2014/B, GRAALL-2014/T and GRAAPH-2014respectively for patients with B-lineage Ph-negative ALL, T-lineage ALL or Ph+ ALL. France, S...
Clinical Studies - Jun 3, 2016 - May 31, 2026
Ongoing
Project leader: Silzle Tobias
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
May 27, 2016Each subject will participate in the trial from the time the subject signs the Informed Consent Form (ICF) through the final contact. After a screening phase of up to 42 days, eligible subjects can be randomized to either pembrolizumab (experimental...
Clinical Studies - May 27, 2016 - Nov 30, 2020
Automatically Closed
Project leader: Weisshaupt Christian
SAKK 08/14 Investigation of Metformin in patients with castration resistant Prostate Cancer in combination with Enzalu-tamide vs. Enzalutamide alone (IMPROVE TRIAL)
May 20, 2016The current standard of care for patients with metastatic castration resistant prostate cancer (mCRPC) and dis-ease progression is either treatment with abiraterone acetate and prednisone in asymptomatic or mildly symp-tomatic patients without viscer...
Clinical Studies - May 20, 2016 - Jul 31, 2026
Ongoing
Project leader: Rothermundt Christian
Klinische Phase-I-Studie zur Beurteilung der Sicherheit, der pharmakokinetischen Profile sowie der Wirksamkeit von EDO-S101, einem First-in-Class alkylierenden HDA-Ci-Fusionsmolekül, bei rezidivierenden/refraktären häma-tologischen Malignitäten
May 4, 2016Es handelt sich um eine zweistufige Phase-I-Studie. Stufe 1 der Studie dient der Bestimmung der MTD, der Identifika-tion der empfohlenen Stufe-II-Dosierung sowie der Ermitt-lung der optimalen Infusionsdauer. Stufe 2 dient der Bestä-tigung der Sicherh...
Clinical Studies - May 4, 2016 - Jan 1, 2018
Automatically Closed
Project leader: Driessen Christoph
A phase III, open-label, randomized study of MPDL3280A (AntiPD-L1 antibody) in combination with carboplatin Paclitaxel with or without bevacizumab compared with carboplatin Paclitaxel bevacizumab in chemotherapy naïve patients with stage IV non-squamous non-small cell lung cancer
Apr 14, 2016MPDL3280A ist ein humaner monoklonaler Antikörper der Immunglobulin (Ig)-Klasse G1 und wird in den Ovarialzellen des chinesischen Hamsters produziert. MPDL3280A wird als mögliche Therapie gegen solide Tumore und hämatologische Malignitäten in Mensche...
Clinical Studies - Apr 14, 2016 - Apr 14, 2020
Automatically Closed
Project leader: Früh Martin
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
Mar 30, 2016Primary/co-primary. To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (lobectomy/pneumonectomy) with or with-out standard adjuvant chemotherapy for stage IB (T ≥ 4 cm) -II-IIIA NSCLC patien...
Clinical Studies - Mar 30, 2016 - Mar 30, 2020
Automatically Closed
Project leader: Früh Martin
Merck EORTC 1325 / MK-3475-054 - Adjuvant immunotherapy with anti-PD-1 monoclonal anti-body Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A ran-domized, double- blind Phase 3 trial of the EORTC Mela-noma Group
Mar 1, 2016This is an international, double-blinded, placebo-controlled randomized phase III trial. Enrollment will be a multi-step process. Randomization (placebo vs. pembrolizumab) will be performed centrally and will be stratified for the following factors:...
Clinical Studies - Mar 1, 2016 - Mar 1, 2020
Automatically Closed
Project leader: Fehr Martin
SAKK 41/14 ACTIVE-2: PHYSICAL ACTIVITY IN PATIENTS WITH METASTATIC
Feb 23, 2016
Clinical Studies - Feb 23, 2016 - May 31, 2021
Automatically Closed
Project leader: Horber Daniel
Single arm open label phase II pilot study of carboplatin in patients with metastatic castration-resistant prostate cancer (CRPC) and PTEN-loss and/or DNA repair defects. PRO-PLAT
Feb 17, 2016Clinical studies in unselected prostate cancer patients strongly support the hypothesis that platinums have anti-tumour activity in some patients with CRPC. For patients progressing after docetaxel based chemotherapy and a novel androgen receptor tar...
Clinical Studies - Feb 17, 2016 - Jan 1, 2019
Automatically Closed
Project leader: Omlin Aurelius
Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial
Jan 20, 2016Dickdarmkrebs gehört zu den häufigsten bösartigen Tumoren weltweit. Die meisten Patienten mit Dickdarmkrebs unterziehen sich einer Operation. Trotz kompletter Entfernung des Dickdarmkrebs und eventuell zusätzlicher Chemotherapie ist jedoch das Risiko...
Clinical Studies - Jan 20, 2016 - Feb 1, 2028
Ongoing
Project leader: Gueller Ulrich
Liver metastasis in colorectal carcinoma: Accuracy of Contrast-enhanced ultrasound (CEUS) in comparison with computertomography on new diagnosed CRC with impact on therapy strategy?
Dec 1, 2015Background: Up to 20% of liver metastasis could be missed by CT according to the oncological staging in colorectal carcinoma Primary endpoint: Detection of colorectal liver metastasis (CRLM) – comparison of CEUS with CT (hypothesis CEUS with better s...
Clinical Studies - Dec 1, 2015 - Nov 1, 2018
Automatically Closed
Project leader: Sawatzki Mikael
Members: Alfter Christine, Semela David, Gueller Ulrich, Horber Daniel, Bergamin Irina
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
Oct 26, 2015Es handelt sich um eine randomisierte open label Phase III Studie. Die Patienten werden vom Hauptsitz der EORTC zentral im Verhältnis 1:1 für die Therapie mit Enzalutamid oder Enzalutamid (Standartbehandlung) und Ra223 (experi-mentelle Behandlung) ra...
Clinical Studies - Oct 26, 2015 - Dec 31, 2030
Ongoing
Project leader: Rothermundt Christian
Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial
Oct 15, 2015Der Behandlungsansatz beim FL sah bislang entweder ein zunächst abwartendes Beobachten beim asymptomati-schen Patienten oder aber monotherapeutische Behand-lungen vor, mit dem Ziel, möglichst lange eine gute Le-bensqualität zu erhalten. Für die asymp...
Clinical Studies - Oct 15, 2015 - Dec 31, 2029
Ongoing
Project leader: Hitz Felicitas
Members: Silzle Tobias, Fehr Martin, Fischer Stefanie
Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial
Sep 9, 2015Das Mantelzelllymphom zeichnet sich durch eine für B-Zell Lymphome vergleichsweise schlechte Prognose aus. Dies erklärt sich durch häufige Rückfälle und dem meist ausgedehnten Krankheitsstadium und höherem Alter (median 60-65 Jahre) bei Diagnosestell...
Clinical Studies - Sep 9, 2015 - Mar 31, 2021
Automatically Closed
Project leader: Driessen Christoph
Members: Hitz Felicitas, Fehr Martin, Hess Urs, Hess Dagmar, Silzle Tobias
Eribulin as 1st line treatment in elderly patients (≥ 70 years) with advanced breast cancer: a multicenter phase II trial
Aug 11, 2015Es wird die Wirksamkeit und die Verträglichkeit von Eribulin als palliative Erstlinien-Chemotherapie bei älteren Brustkrebspatientinnen ((≥ 70 J.) untersucht. Es soll gezeigt werden, dass eine gegenüber den Registrierungs-Studien leicht reduzierte St...
Clinical Studies - Aug 11, 2015 - Jun 30, 2019
Automatically Closed
Project leader: Hasler-Strub Ursula
Members: Thürlimann Beat, Ruhstaller Thomas, Riniker Salome, Weder Patrik, Schmid Sabine, Magayakalbermatten N
An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors
Jul 8, 2015MO29518 ist eine offene, multizentrische, multinationale Phase-II-Studie mit 10 Kohorten, welche MPDL3280A (Anti-PD-L1 Antikörper) bei Patienten mit fortgeschrittenen soliden Tumoren untersucht (Gebärmutterhalskrebs, Nasen-Rachenkrebs, spezielle Art...
Clinical Studies - Jul 8, 2015 - Jul 31, 2019
Automatically Closed
Project leader: Gillessen Sommer Silke
Members: Schmid Sabine, Fischer Stefanie, Rothermundt Christian, Templeton Arnoud, Omlin Aurelius, Desax Marie-Claire, Früh Martin, Weisshaupt Christian